BJDX - התחייבויות לטווח ארוך להון Bluejay Diagnostics Corp

Bluejay Diagnostics (BJDX) develops rapid diagnostic systems, yet a lack of revenue and reliance on new share issuances leave the business extremely vulnerable, as confirmed by the financial price action with the 0.00 indicator. There is a serious threat of failure during product market entry and difficulties with equipment implementation in clinics. The company's strategy relies on independent platform promotion and limited licensing of distribution rights.

This ratio is calculated by dividing total liabilities with a maturity of over one year by the amount of equity. By analyzing the ratio of long-term loans to equity, an investor determines the degree of financial stability and default risks. A decrease in this metric confirms a reduction in debt, whereas an excess limits business maneuverability. For Bluejay Diagnostics (BJDX), the leverage balance is critical when building a staff of high-caliber researchers. Stable financing allows Bluejay Diagnostics (BJDX) to provide premium working conditions for developers of rapid diagnostic systems.